Viridian Therapeutics, Inc.
VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the trā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$24.29
Price-0.86%
-$0.21
1Y
Price
Market Cap
$2.752b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-71856.7%
EBITDA Margin-74397.9%
Net Profit Margin-84877.3%
Free Cash Flow Margin-71856.7%
EBITDA Margin-74397.9%
Net Profit Margin-84877.3%
Free Cash Flow MarginRevenue
$70.918m
+0.1%
1y CAGR+7785.4%
3y CAGR+5818.5%
5y CAGREarnings
-$360.590m
-5.2%
1y CAGR-15.2%
3y CAGR-32.2%
5y CAGREPS
-$3.48
-4.8%
1y CAGR+12.3%
3y CAGR+0.3%
5y CAGRBook Value
$636.008m
$789.017m
Assets$153.009m
Liabilities$51.174m
DebtDebt to Assets
6.5%
-0.1x
Debt to EBITDAFree Cash Flow
-$303.824m
-9.7%
1y CAGR-18.1%
3y CAGR-37.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company